This study was designed to determine the effects of PPAR lack on cardiac mechanical performance and to identify potential intracellular mechanisms linking PPAR pathway deficiency to cardiac contractile dysfunction. Echocardiography, ex vivo papillary muscle assays and in vitro motility assays were used to assess global, intrinsic ventricular muscle performance and myosin mechanical properties respectively in PPAR -/-and age-matched wild-type mice. Three-nitrotyrosine formation and 4-hydroxy-2-nonenal protein-adducts, both markers of oxidative damage, were analyzed by Western blotting and immunolabeling. Radical , with no changes in copper-zinc superoxide dismutase, catalase or glutathione peroxidase. These findings demonstrate that PPAR pathway deficiency impairs cardiac function and also identify oxidative damage to myosin as a link between PPAR deficiency and contractile dysfunction.
Introduction
The peroxisome proliferator-activated receptor (PPAR , / and ) family of lipidactivated nuclear receptors plays a critical role in the gene regulation of cellular lipid metabolism (10) . In cardiac muscle, PPAR is expressed at relatively abundant levels and activates numerous genes involved in cellular fatty acid uptake and oxidation (10) .
Interestingly, PPAR gene regulatory pathway activity is down-regulated in hypertrophied heart (2) and in the human failing heart (2, 40, 43) . It is unclear whether this metabolic shift, with increased reliance on glucose metabolism rather than fatty acid oxidation, is a protective response allowing the heart to maintain contractile function or an initial step leading to progressive deterioration of contractile function (2, 33) . The functional and biologic roles of PPARL in cardiac muscle have been widely investigated through the PPAR -/-mouse model (5, 11, 47) . Although PPAR -/-mice have a normal life span, they develop progressive cardiac fibrosis and myofibrillar fragmentation associated with abnormal mitochondrial ultrastructure (47) . Reduced cardiac contractile performance at baseline (26) or in response to increased workload (27) has been recently reported in PPAR -/-mice. However, the precise consequences of chronic PPAR deficiency on the cardiac contractile apparatus and muscle performance remain to be established.
There is increasing evidence that a proper balance between oxidants and antioxidant defenses is required to maintain normal cardiac function (3, 12, 30, 39) . Depletion in antioxidant enzymes such as superoxide dismutase (SOD), catalase, and glutathione peroxidase (GPX) (39) or overproduction of reactive oxygen species (ROS) or reactive nitrogen species (RNS) may induce oxidative stress and cause cardiac functional disorders (12, 39) . Recently, increased PPAR activity and fatty acid oxidation have been associated with an increase in reactive oxygen intermediates (42) . However, there is also strong evidence that activation of PPAR is necessary to prevent cellular oxidative damage that may occur during physiological cellular metabolism or under conditions of inflammation and oxidative stress, probably through repressing nuclear factor-B signaling and reducing inflammatory cytokine production (38, 44, 45) . Therefore, it is possible that chronic deactivation of the PPAR signaling pathway upsets normal equilibrium between oxidant production and antioxidant defenses and contributes to cardiac damage.
The first aim of our study was to identify the effects of chronic deficiency in the PPAR pathway on cardiac dysfunction. To this end, echocardiography, in vitro papillary muscle mechanics and motility assays with purified myosin molecules were performed in PPAR -/-mice. We then aimed to identify the mechanisms involved in cardiac dysfunction. We tested the hypothesis that oxidative damage occurred in PPAR -/-hearts by using markers of protein oxidation (4-hydroxy-2-nonenal protein-adducts) and a marker of peroxynitrite and/or nitrosative stress (3-nitrotyrosine formation) (35) . Finally, the cardiac levels and activities of several intracellular antioxidant enzymes were analyzed in order to assess the radical scavenging capacity in PPAR -/-hearts. To this end, protein levels and/or activities of the H 2 O 2 scavenging enzymes catalase and GPX and the two intracellular O 2 .-dismutating enzyme copper-zinc (Cu/Zn-SOD, cytosolic) and manganese superoxide dismutase (Mn-SOD, mitochondrial) were examined.
We found that the lack of PPAR was primarily responsible for the development of intrinsic cardiac dysfunction associated with mechanical impairment of myosin and we identified oxidative damage to myosin as a link between PPAR deficiency and cardiac contractile dysfunction. 6 NC). Ten consecutive measurements were performed after a training period. Artifactual and aberrant tracings due to movements of the mice were discarded and a mean value was generated for each individual mouse.
Antibodies. Rabbit polyclonal anti-MnSOD and anti-Cu/Zn antibodies were purchased from Stressgen. Rabbit polyclonal anti-catalase and anti-4-hydroxy-2-nonenal antibodies were from Calbiochem, mouse monoclonal anti-3-nitrotyrosin antibody was purchased from Santa Cruz. Mouse monoclonal anti-actinin, anti-myosin, anti-vinculin antibodies and rabbit polyclonal anti-actin antibody were purchased from Sigma. Secondary anti-rabbit IgG FITCconjugated, anti-mouse and anti-rabbit horseradish peroxidase-conjugated antibodies were from Amersham. Biotinylated anti-mouse IgG antibody was from Vector, and anti-mouse IgG Alexa Fluor 488 was purchased from Molecular Probes.
Histology and Immunofluorescence analysis. Histology was performed on ventricular formalin-fixed tissue embedded in paraffin. Sections of 5 Qm thickness were stained by haematoxylin-eosin-saffron (HES) and Masson trichrome. Additional hearts were snap frozen in liquid nitrogen and stained with Oil Red O or used for immunofluorescence analysis. LV cryosections of 5 Qm-width were air-dried, fixed in 4% formalin for 15 min and saturated with 5% bovine serum albumin (BSA) in phosphate-buffered saline (PBS) for 30 min. Sections were incubated for 90 min at room temperature with primary antibodies (anti-vinculin, dilution 7 secondary antibodies were used as negative controls and showed very low background staining.
Fluorescence was visualized using a DMRBE Leica microscope equipped with a 40x-oil epifluorescence objective. Morphometry was performed using IPlab software. A minimum of 50 myocytes/field and 5-8 field/heart were measured.
Papillary muscle mechanics.
Mechanical experiments were performed on LV papillary muscle. After anesthesia with pentobarbital, the heart was rapidly excised and placed in a physiological solution. The LV was opened under a dissection microscope and one papillary muscle was carefully dissected. The muscle was then placed in a circulating organ bath containing modified Krebs Henseleit buffer solution (22) . The solution was bubbled with 95% O 2 and 5% CO 2 and maintained at 29°C and pH 7.4 to ensure good mechanical stability. One extremity of the papillary muscle was held by a stationary clip and the other was maintained with another clip attached to an isotonic electromagnetic force-transducer lever. In brief, a precision current source delivers the current through the coil and hence determines the force at the tip of the lever. The displacement of the lever is measured with an opto-electronic transducer. The length range is 1000 Qm with a maximal error of 1% and the maximum force range corresponds to a load of 20 mN at the lever tip, with a noise floor of 0.01 mN. The force transducer we used enabled us to analyze mechanical performance over the whole load continuum. After an equilibration period of 30 min, muscle was supramaximally stimulated using two platinum electrodes at the optimal force-frequency response, i.e. at a frequency of 6/min. Experiments were performed at Lmax, the initial muscle length at which active isometric tension was maximum. Muscle force was normalized per cross-sectional area (CSA) at the middle part of the muscle using the following approximation: CSA=0.75 x width x depth (24).
The mechanical parameters were calculated from 3 different loaded contractions: contraction 1 was loaded with preload only and abruptly clamped to zero-load just after stimulus according to the zero-load clamp technique (4). Contraction 2 was loaded with preload only. Contraction 3 was carried out against a heavy load that the muscle could not overcome, so its contraction was fully isometric. During the contraction phase, we recorded the maximum unloaded shortening velocity (Vmax, in Lmax.s -1 ) of contraction 1, the maximum extent of muscle shortening of contraction 2 ( L, in % Lmax), the peak isometric tension, i.e. peak force normalized per crosssectional area (Pmax, in mN.mm -2 ) of contraction 3, and the positive peak of isometric tension derivative of contraction 3 (+dP/dt, mN.mm -2 .s -1 ).
In vitro motility assays. Purified myosin obtained from LV was assessed by gel electrophoresis (19) . F-actin was prepared from rabbit skeletal muscle by standard methods (36) and fluorescently labeled with phalloidin FluoProbes 547 (Interchim, France). Motility assays were carried out at 29°C as previously described (7). The movement of actin filaments was observed under a Zeiss epifluorescence microscope (Axiovert 200, 100/1.30 lens, Jena, Germany) equipped with an intensified camera (Hamamatsu C 2400, Hamamatsu City, Japan) and recorded on videotape. The mean velocities of each filament were analyzed using N.J.
Carter's freeware RETRAC program.
Western blotting. Western blotting was performed on total protein extracts and myosin fractions obtained from LV tissues. Protein concentrations were determined using the BCA protein assay kit (Pierce) according to the manufacturer's instructions. The samples were stored at -20°C until use. Proteins were separated by 9 or 12% SDS-polyacrylamide gel electrophoresis (PAGE). Western-blot analysis was performed using anti-MnSOD (1:1000) anti-Cu/ZnSOD (1:1000), anti-catalase (1:1000), anti-4-hydroxy-2-nonenal (HNE) (1:1000), and anti-3-nitrotyrosine (1:500) antibodies. Detection was performed using anti-mouse or antirabbit horseradish peroxidase labeled antibodies (1/5000). Membranes were revealed with ECL chemiluminescent substrate (Amersham). Light emission was detected with a highly sensitive imaging system (Fujifilm LAS-3000). Signals were quantified using Image Gauge software and normalized to the expression of actin or myosin.
Myosin isoform composition. Myosin isoform composition was determined on purified myosin stored in 50% glycerol. V1 and V3 myosin were separated on 8% polyacrylamide gels containing 10% glycerol (41) . SDS-PAGE was performed in a BioRad Mini-Protean II Dual Slab Cell electrophoresis system for 16 h at 4° C and 70 V. Gels were stained with Coomassie blue and quantification of V1 and V3 was performed using Image Gauge software.
Antioxidant enzymatic activities.
To measure the activities of Cu/Zn-SOD, Mn-SOD, catalase and GPX, frozen heart tissues were homogenized in 10 mM phosphate buffer, pH 7.8, EDTA 1 mM (8) . The activities of SOD were measured using xanthine/xanthine oxidase to generate superoxide radicals which react with 2-(4-iodophenyl)-3-(4-nitrophenol)-5-phenyltetrazolium chloride (INT) to form a red formazan dye with maximum absorbance at 550 nm. SOD activity was then measured by the degree of inhibition of this reaction. One unit of SOD was defined as the amount of enzyme causing a 50% inhibition of the rate of reduction of INT (Randox Laboratories, UK). Total SOD activity was measured at pH 7.8, and Cu/Zn SOD activity, primarily located in the cytosol, was measured at pH 10.2. The activity of MnSOD, exclusively located in the mitochondria matrix, was obtained by subtracting Cu/Zn SOD activity from total SOD activity (29) . GPX activity was determined using an indirect, coupled test procedure with terbutyl peroxide as a substrate (34) . Catalase activity was measured according to Johansson and Borg's method (17) . To minimize within-run variations, each sample was measured in duplicate. Activities are expressed in units normalized per mg of protein (U/mg).
Statistics. Data are expressed as mean ± SEM. Comparisons were made using Student's unpaired t-test. Differences were considered significant at p<0.05.
Results
Cardiac morphometry and structure. Body weight was about 20% higher in PPAR Gross examination of the heart of PPAR -/-mice did not reveal abnormalities (Fig. 1, a and b) .
Morphometric analysis was performed on longitudinal (Fig. 1, c and d) and transversal ( and WT mice respectively, p<0.005; Fig. 2C ). Heart rate at baseline did not differ between groups (Fig. 2D ) and telemetric ambulatory ECG measurements did not evidence conduction or excitability defects.
Intrinsic mechanical performance of in vitro LV papillary muscle. Intrinsic mechanical parameters were recorded from 3 different loaded contractions (Fig. 3A) . No difference between groups was observed in the morphometric characteristics of the LV papillary muscles (Table 2 ). Vmax and L were respectively 75% and 50% lower in PPAR -/-than in WT (Fig. 3, B and C), thus attesting to severe depression of shortening capacities in PPAR -/-mice. In addition, peak isometric tension and +dP/dt were respectively 50% and 80% lower in PPAR -/-than in WT (Figure 3, D and E) .
Myosin molecular properties. In vitro motility assays were performed using purified LV myosin monomers. As shown in Figure 4A , the mean velocity of actin filaments driven by myosin extracted from PPAR -/-mice was 16% slower than the control rate (p<0.01). Given that only myosin and not actin differed between groups under our experimental conditions, these data indicated that intrinsic alterations in myosin mechanical function occurred in LV from PPAR -/-mice.
Myosin isoforms.
To determine whether reduced shortening capacities in PPAR -/-were related to -to -myosin isoform shift, MHC expression patterns were determined by electrophoresis (Fig. 4B) . The amount of -MHC and -MHC represented respectively 86 ± 3% and 14 ± 3% of total MHC isoform in WT. No significant shift in the -to -MHC ratio was present in LV from PPAR -/-mice (Fig. 4B) .
Oxidative damage to contractile proteins. To determine whether oxidative damage to contractile proteins and particularly myosin contributed to reduced contractility in PPAR -/-, we next examined protein tyrosine-nitration and HNE-adduct formation using both tissue samples and protein extracts. Immunohistochemistry studies revealed pronounced cytosolic and membrane-associated 3-nitrotyrosine (3NT) staining in PPAR -/-but not in control cardiomyocytes (Fig. 5, A and B) . Importantly, in both myosin and total protein extracts, MHC was identified by Western Blot as the main nitrated protein and analysis revealed a two-fold higher 3NT-MHC in PPAR -/-compared with WT mice (Fig. 6A, p<0.01) . In control and PPAR -/-hearts, enhanced chemiluminescence revealed additional 3NT-bands of lower molecular weights (MW ዊ 60, 47 and 43 kDa, respectively) but whose quantification did not differ between groups. HNE-protein adduct, a marker of lipid peroxidation, was detectable in control and PPAR -/-myocardium, the main HNE-conjugated band being at 75 kD (Fig. 6B) .
The amount of this 75-kD band was nearly 3-fold higher in PPAR -/-than in WT mice (p<0.01). No evidence of myosin modification by HNE was detected in myosin extracts.
Antioxidant enzyme protein expression. As shown in Figure 5C (Fig. 7A) . In contrast, there were no significant differences in the protein expression of Cu/ZnSOD and catalase between PPAR -/-and WT mice (Fig. 7, B and C) .
Antioxidant enzyme activities. Antioxidant enzyme activities are illustrated in Figure 7 .
PPAR -/-
hearts displayed a 50% reduction in MnSOD activity compared with WT (p<0.01, Figure 7A ). There were no significant differences in Cu/ZnSOD (Fig. 7B), catalase (Fig. 7C) and GPX (Fig. 7D) (Fig. 1) . Given that the heart weight/body weight ratio did not differ between WT and PPAR -/-mice, these data indicated a loss of cardiomyocytes in PPAR -/-compared with WT, i.e., that apoptosis and/or fibrosis occurred in heart from PPAR -/-. Accordingly, we found that intrinsic papillary muscle performance was depressed in PPAR -/-mice (Fig. 3) .
Several mechanisms could help explain why this occurred, despite a moderate reduction in fractional shortening on echocardiography. First, reduced LV fractional shortening in PPAR -/-was not related to an increased in afterload since SBP was lower in PPAR -/-mice than in WT ( Figure 2C ). Given that reduction in SBP is expected to induce an increase in LV fractional, in vivo cardiac contractility in PPAR -/-mice could be more severely impaired than that evaluated by echocardiography. Second, the depression of intrinsic papillary muscle performance may involve a low rate of -oxidation and ATP production induced by the deletion of PPAR (27, 47) . These findings attest to energetic deprivation in PPAR -/-heart (27, 47), whose functional consequences may differ between in vivo and in vitro conditions. Indeed, it has been shown that the use of fatty acids in the perfusion medium prevents contractile abnormalities of isolated working heart preparation (26) . In contrast, the ex vivo cardiac performance of PPAR -/-mice was reduced when the perfusion medium contained only glucose as a substrate (26), i.e., in conditions where muscle energy was produced by glycolysis and glucose oxidation. In our isolated papillary muscle experiments, the bathing medium contained only glucose as a substrate. Although such bathing conditions are optimal in papillary muscle from wild-type mice, they could contribute to reduced intrinsic mechanical performance in PPAR -/-. In addition, in our isolated papillary muscle experiments, the bathing medium was continuously bubbled with 95% O 2 and 5% CO 2 . This results in a high oxygen partial pressure that may increase the production of reactive oxygen species and oxidative stress within cardiomyocytes, and in turn could contribute to decreased in vitro muscle mechanical performance in PPAR -/-. Finally, it is widely recognized that functional impairment does not necessarily correlate between in vivo and in vitro conditions, especially in mice, and that experimental in vitro conditions could unmask and exacerbate even moderate intrinsic dysfunction (16, 18) .
We then explored the mechanical function of myosin, the molecular motor of the heart which generates force and motion by coupling its ATPase activity to its cyclic interaction with actin. We found that the in vitro capacity of myosin to propel actin filaments was reduced in PPAR -/-heart ( Figure 4A ), thereby strongly suggesting that pathological processes affecting the myosin molecule itself were involved in cardiac dysfunction in PPAR -/-mice (7, 14, 19) .
We therefore sought to identify intracellular pathways and protein targets linking PPAR deficiency to cardiac contractile dysfunction. Because -and -MHC, the two MHC isoforms expressed in mammalian heart, have profound functional differences in terms of shortening velocity, force generation and ATPase activity (14, 21) . In adult mice, -MHC expression normally predominates in the ventricles (31) but a cardiac MHC isoform shift can be achieved by pleiotropic stimuli, such as hypertrophy or changes in hormonal status (15, 21, 31) . No changes in MHC isoform content were observed in PPAR -/-mice, so that changes in heart function cannot be ascribed to modifications in MHC isoform content.
Oxidative damage and PPAR deficiency. PPAR has an important role in the control of various types of inflammatory response (9) . In non-cardiac tissues, there is strong evidence that normal PPAR function is necessary to protect cells from oxidative damage mediated by superoxide radicals generated during normal cellular metabolism or under conditions of inflammation and oxidative stress (38) . Spleen and liver from PPAR -/-mice express indicators of oxidative stress much earlier in their lifespan than WT mice and PPAR agonists help to prevent oxidative damage in aged WT mice (38) . In heart, myofibrillar (6, 30) as well as mitochondrial (6, 32) proteins are major targets of oxidative stress-derived effects and oxidative and/or nitrosative changes in proteins have been shown to modulate cardiac function (3, 39) .
Therefore, we hypothesized that oxidative and/or nitrosative modification of contractile proteins contribute to cardiac dysfunction in PPAR -/-mice. Among the different modifications induced by peroxynitrite and other RNS, that of protein tyrosine-nitration is one of the best characterized in several cardiomyopathies (3, 35, 39) . Notably, we found that myosin heavy chain was one of the major targets of protein tyrosine nitration in PPAR -/-hearts (Fig. 6 ).
Given that in vitro tyrosine-nitration of myosin reduces sliding velocity (personal data), it is entirely conceivable that alterations caused in the conformation of myosin by its nitration account for the reduced myosin-based velocity observed in PPAR Protection against oxidative damage is accomplished by a complex defense system composed of antioxidant molecules and antioxidant enzymes that reduce the damaging effects of ROS by converting more reactive species to less reactive and less damaging forms (13) . The SODs act as a first line of defense against oxygen free radical-mediated damage by catalyzing the dismutation of superoxide anions to hydrogen peroxide (H2O2). Subsequently, H2O2 is reduced to H2O and O2 by peroxidases (e.g., GPX) or catalase (13) . Regulation of MnSOD is considered to play a crucial role in cardiac oxidative stress (25, 46) . Our results clearly demonstrate a substantial decrease in MnSOD expression in PPAR -/-hearts compared with WT, associated with an even more pronounced decrease in enzymatic activity (Fig. 7) , which would suggest enzyme inactivation (25, 46) . These decreases were likely to increase the level of superoxide, which in turn may react with the NO to form the powerful oxidant peroxynitrite and induce protein nitration. Our data suggest that in addition to its metabolic regulatory effects, PPAR was also involved in the maintenance of cardiac oxidant/antioxidant balance.
In conclusion, we demonstrated that lack of PPAR was responsible for the development of reduced cardiac contractile function related at least in part to direct tyrosinenitration of myosin and increased lipid peroxidation in the heart of PPAR Values are means ± SEM; N=8 in WT and N=10 in PPAR -/-group. Lmax, muscle length at preload corresponding to peak of length-active tension curve; CSA, cross-sectional area. 
